Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

NCRI 2018 | Glioma biomarker research

Kathreena Kurian • 8 Nov 2018
NCRI 2018
Brain Tumor Glioma

Waiting for pathology results to determine the grade of glioma tissue prior to surgery requires time, which can be improved with the use of real-time visible markers. Kathreena Kurian, MBBS, MD, FRCPath (Neuro), from the University of Bristol, Bristol, UK, thinks that the combination of histopathological and intraoperative biomarkers could be the way forward, as she explains here. This interview was recorded at the 2018 National Cancer Research Institute (NCRI) Cancer Conference, held in Glasgow, UK.

More from Kathreena Kurian

2:37
Improving glioma surgery using a real time fluorescence biomarker
Kathreena Kurian • 8 Nov 2018

Related Videos

0:54
Identifying molecular biomarkers for treatment response to bortezomib in glioblastoma
Martha Chekenya • 7 Apr 2024
1:41
Sequential bortezomib and temozolomide in recurrent glioblastoma
Mohummad Rahman • 7 Apr 2024
3:13
Challenges in glioblastoma treatment: bortezomib trial for improved outcomes
Martha Chekenya • 7 Apr 2024
4:06
Multidisciplinary approaches in treating brain tumors: current landscape and future directions
Glenn Lesser • 12 Mar 2024
The content of VJOncology is intended for healthcare professionals